Mandy Fraessdorf

TL;DR: Patients who experienced major bleed on dabigatran required more red cell transfusions but received less plasma, required a shorter stay in intensive care, and had a trend to lower mortality compared with those who had major bleeding on warfarin.

TL;DR: In patients who interrupted dabigatran or warfarin for a surgery/ procedure in the RE-LY trial, use of bridging anticoagulation appeared to increase the risk for major bleeding irrespective of dabig atran orwarfarin interruption.

TL;DR: The effects of dabigatran compared with warfarin in the subgroup of patients with previous symptomatic heart failure in the RE‐LY trial are evaluated.

TL;DR: During a 6-month period, pramipexole was effective, safe, and generally well tolerated, and because risk of augmentation may have increased over 6 months, it should be studied in longer trials.

TL;DR: The efficacy and safety of dabigatran etexilate were not significantly affected by the presence of thrombophilia or APS, and rates of bleeding events tended to be lower with dabig atran e Texilate than with warfarin, reaching statistical significance for any bleeding event.